Pfizer-BioNTech
Ages 6 months–4 years

- **DOSE 1**
  - PRIMARY
  - 3 μg/0.2 mL
  - In 3 weeks

- **DOSE 2**
  - PRIMARY
  - 3 μg/0.2 mL
  - In at least 8 weeks

- **DOSE 3**
  - PRIMARY
  - 3 μg/0.2 mL
  - In at least 8 weeks

Maroon Cap

Pfizer-BioNTech
Ages 5 years–11 years

- **DOSE 1**
  - PRIMARY
  - 10 μg/0.2 mL
  - In 3 weeks

- **DOSE 2**
  - PRIMARY
  - 10 μg/0.2 mL
  - In at least 4 weeks

- **DOSE 3**
  - PRIMARY
  - 10 μg/0.2 mL
  - In at least 3 months

- **DOSE 4**
  - BOOSTER
  - 10 μg/0.2 mL
  - In at least 3 months

Orange Cap

Pfizer-BioNTech
Ages 12 years and older

- **DOSE 1**
  - PRIMARY
  - 30 μg/0.3 mL
  - In 3 weeks

- **DOSE 2**
  - PRIMARY
  - 30 μg/0.3 mL
  - In at least 4 weeks

- **DOSE 3**
  - PRIMARY
  - 30 μg/0.3 mL
  - In at least 3 months

- **DOSE 4**
  - BOOSTER
  - 30 μg/0.3 mL
  - In at least 4 months

- **DOSE 5**
  - BOOSTER
  - 30 μg/0.3 mL
  - In at least 4 months

Gray Cap

---

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: CDC.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.